Objective: Post-traumatic stress disorder (PTSD) has major public health significance. Evidence that PTSD may be associated with premature senescence (early or accelerated aging) would have major implications for quality of life and healthcare policy. We conducted a comprehensive review of published empirical studies relevant to early aging in PTSD. Method: Our search included the PubMed, PsycINFO, and PI-LOTS databases for empirical reports published since the year 2000 relevant to early senescence and PTSD, including: 1) biomarkers of senescence (leukocyte telomere length [LTL] and pro-inflammatory markers), 2) prevalence of senescence-associated medical conditions, and 3) mortality rates. Results: All six studies examining LTL indicated reduced LTL in PTSD (pooled Cohen's d ¼ 0.76). We also found consistent evidence of increased pro-inflammatory markers in PTSD (mean Cohen's ds), including C-reactive protein ¼ 0.18, Interleukin-1 beta ¼ 0.44, Interleukin-6 ¼ 0.78, and tumor necrosis factor alpha ¼ 0.81. The majority of reviewed studies also indicated increased medical comorbidity among several targeted conditions known to be associated with normal aging, including cardiovascular disease, type 2 diabetes mellitus, gastrointestinal ulcer disease, and dementia. We also found seven of 10 studies indicated PTSD to be associated with earlier mortality (average hazard ratio: 1.29). Conclusion: In short, evidence from multiple lines of investigation suggests that PTSD may be associated with a phenotype of accelerated senescence. Further research is critical to understand the nature of this association. There may be a need to re-conceptualize PTSD beyond the boundaries of mental illness, and instead as a full systemic disorder. (Am J Geriatr Psychiatry 2015; 23:709e725) 
I n recent years, there has been growing concern that psychiatric disorders such as schizophrenia, bipolar disorder, and major depression are associated with significant medical comorbidity, and that some of this morbidity may reflect an acceleration of the aging process.
1e4 Post-traumatic stress disorder (PTSD) is an important public health concern in the United States, particularly since 9/11/2001 and conflicts in Iraq and Afghanistan. Because of the importance of stress in various aspects of the aging process, 5 we considered that PTSD may also show an association with early senescence. To investigate this hypothesis further, we performed a review of the relevant literature. What constitutes evidence for premature or accelerated senescence has not been standardized, but in non-psychiatric conditions reportedly associated with early senescence, such as HutchinsonGilford Progeria syndrome, Werner syndrome, HIV infection, and Down syndrome, the majority of the evidence falls into three categories: biological indicators/biomarkers, earlier occurrence or higher prevalence of medical conditions associated with advanced age, and premature mortality.
6e12 These categories formed the basis for our literature search into the possible association of PTSD with accelerated senescence. The present review was conducted to evaluate evidence for early or accelerated senescence in PTSD. Given the diversity of outcomes and methods in individual studies, this was not intended as a formal meta-analysis. Nevertheless, where possible, we calculated overall effect sizes for studies of targeted biomarkers and mortality for which there were multiple articles with sufficient overlap in methods and outcomes.
METHODS
We searched PubMed, PsycINFO, and PILOTS databases for papers published between January 1, 2000, and November 30, 2014. The year 2000 was chosen because it included studies published after 9/11/2001 and the wars in Iraq and Afghanistan, which represented the beginning of a period of intensified public and scientific interest in PTSD.
Targeted outcomes for the present review included: biomarkers of senescence (leukocyte telomere length [LTL] , blood pro-inflammatory indices, and oxidative stress), comorbid medical conditions associated with aging (hypertension [HTN] , heart/cardiovascular disease, metabolic syndrome, post-PTSD onset type 2 diabetes mellitus, gastrointestinal ulcer diseases, and dementia), and mortality. Almost any medical condition could potentially be age-associated, but we focused on these conditions because each has empirical evidence of increased incidence with advancing age, is potentially fatal, and tends to be worsened by stress. 13 The last consideration, while ruling out some life-threatening conditions such as cancer, was felt important given the relationship of stress to PTSD. The search of databases was an iterative process resulting in the following search query: (PTSD OR post-traumatic stress OR posttraumatic stress) AND (aging OR ageing OR allostatic OR allostasis OR dementia OR Alzheimer's OR Alzheimer OR Alzheimers OR inflammation OR inflammatory OR longevity OR life expectancy OR length of life OR mortality OR mortalities OR oxidative OR oxidation OR senescence OR telomere OR telomeres OR vascular OR cardiovascular OR metabolic OR diabetes OR ulcer OR ulcers).
We examined the titles and abstracts of all citations returned by these search criteria and selected the empirical English-language reports focused on comparing adults with PTSD (diagnosed with standard criteria) to one or more appropriate comparison groups in terms of aging-related outcomes relevant to this review. We excluded review papers and reports with duplicate data. Other than excluding studies of childhood trauma, we did not exclude studies based on the nature of the precipitating traumatic event. We also searched the bibliography of identified articles for additional relevant papers. Several of the co-authors (JBL, BWP, CAE, SA) participated in the review and selection of potential articles, as well as extraction of the study details and findings, which were agreed on by all the authors.
As noted earlier, the present review was not intended to serve as a formal meta-analysis, but we calculated pooled effect sizes for those targeted outcomes for which there were multiple articles with sufficient overlap in methods and measures to be amenable to such analyses. These included reports involving LTL and pro-inflammatory indices, as well as those for mortality. Given that we were able to calculate pooled effect sizes for most proinflammatory marker studies and hazard ratios for most mortality papers, we excluded a few isolated papers that had insufficient information for such calculations; for example, we excluded three mortality studies for which we could not derive hazard ratio information. 14e16 The calculations of average effect sizes and hazard ratios were conducted using MIX 2.0 software (Biostat XL, http://www.meta-analysismade-easy.com). Individual study effect sizes were synthesized to generate an overall effect size, weighted by the inverse of variance (the latter is partially a function of sample size, thereby calculated effect sizes were weighted by sample size).
RESULTS
Our search yielded 64 studies that met inclusion and exclusion criteria for review (Fig. 1 ). Of these, 22 were suitable for calculating overall effect sizes (Cohen's d) for biomarkers and 10 for mortality (hazard ratio). Interestingly, only two articles that met our inclusion and exclusion criteria were there were no group differences in serum malondialdehyde (an oxidation byproduct), but the PTSD group had lower blood concentrations of erythrocyte superoxide dismutase and erythrocyte glutathione peroxidase, suggesting impaired antioxidant capacity and increased oxidative stress in the PTSD subjects. As part of a magnetic resonance spectroscopy study, Michaels et al. 48 examined the dorsolateral prefrontal cortex and anterior cingulate cortex among 29 traumaexposed individuals (12 with PTSD and 17 without PTSD), and found that those with PTSD had significantly higher levels of the antioxidant glutathione in both regions, which may represent a compensatory reaction to increased oxidation (it may also represent an excess of antioxidant activity for unclear reasons). Ozdemir et al. 49 recently reported a lack of significant group differences in total antioxidant or oxidative status among Turkish earthquake survivors with and without PTSD, and also did not find significant correlations between severity of PTSD symptoms and oxidative measures. Overall, the results from studies of PTSD and oxidative markers appear mixed at best, but given the limited availability of studies with overlapping methods or outcomes measures, and the small samples sizes within several of the available studies, it seems premature to draw firm conclusions regarding the presence or absence of an association of PTSD with oxidative stress.
Studies of Earlier Onset of Senescence-Related Medical Conditions in PTSD
We found 30 studies of association of PTSD with one or more of the targeted medical conditions ( Table 2) . Some of the studies presented results in terms of more than one of the targeted health outcomes, and patterns sometimes differed among the specific conditions. To facilitate interpretation, results were tallied in terms of whether they provided positive, negative, or mixed/ partial support of an associated of PTSD with specific disease categories, with some reports being included in more than one category. Specific references are provided in Table 2 , organized by condition, and whether the findings offered positive, negative, or partial/ mixed support for an association of PTSD with the targeted medical condition. Further details of each study (including sample sizes, sex, mean age, diagnostic methods, study design, key outcomes, and key findings) are available in Supplementary Tables 1e5  (available online) .
Of 12 HTN studies, seven (58%) were positive, 21,50e55 four (33%) were negative, 56e59 and one (8%) reported mixed results 60 ( Table 2 and Supplementary Table 1 [available online]). Of 13 cardiovascular disease studies, 10 (77%) were positive, 21,50,52,55,58,61e65 two (15%) were mixed, 60, 66 and one (8%) was negative 59 (see Table 2 and Supplementary 
Studies of Mortality in PTSD
We found 10 studies (Table 3 ) of comparative mortality rates in PTSD for which hazard ratio data could be calculated. In the context of the present review, the mortality hazard ratio is the risk of a death among those with PTSD at a given point in time relative to the risk of a death in the non-PTSD group at that same point in time. For example, if the hazard ratio is 2.0, then the risk of death for individuals with PTSD at any given point in time is twice the risk of death in individuals without PTSD. Seven studies (70%) reported an increased mortality hazard ratio in the PTSD group compared with comparison subjects. Overall, the pooled hazard ratio (weighted by sample size) was 1.29 (95% CI: 1.11 to 1.5; z ¼ 3.32, p <0.001), indicating a 29% increased risk for mortality in those with PTSD, corresponding to a small to medium effect size.
DISCUSSION
We reviewed 64 studies representing three different categories of evidence linking PTSD with accelerated aging (biomarkers of senescence, senescence-associated medical comorbidities, and mortality rates). We found at least partial evidence of an association in each category, discussed in detail in the following.
Biomarkers Related to Senescence
A majority of studies of LTL and pro-inflammatory markers supported a model of early senescence in PTSD, although not all individual studies supported this, and conclusions must be tempered because of the relatively small number of studies available for comparison. The results for oxidative stress were equivocal, as only five studies were recovered and the methods and outcomes were too diverse to permit firm conclusions about the presence or absence of an association of PTSD with oxidative stress, 18,46e49 although there are theoretical reasons to expect such an association. 45 Pooled effect sizes of LTL and pro-inflammatory biomarkers were Notes: Studies categorized as "Positive" are those for which the study results indicated PTSD was associated with increased prevalence or earlier onset of the medical condition under investigation. "Negative" studies were those for which no significant effects of PTSD on prevalence or onset of the comorbid condition was found. "Mixed" studies were those in which a significant effect of PTSD on medical comorbidity was found in some but not all subset of participants or analyses. HC: healthy comparison subject; MDD: major depressive disorder; PH: Purple Heart; POW: prisoner of war; PTSD: post-traumatic stress disorder; þPTSD: diagnosed with PTSD; ÀPTSD: no PTSD; RPW¼ repatriated POW. generally consistent with an association of PTSD with senescent-like changes. The nature of this relationship is not known. Some investigators suggest that shorter LTL may be a risk factor for PTSD, 24 whereas others contend that LTL may be shortened as a result of a traumatic event or the onset of PTSD. 25e27 Prospective longitudinal research-either measuring LTL among those pre-and post-trauma, or repeatedly measuring LTL among people with PTSDwould be helpful in disentangling these possibilities. The biochemical/molecular mechanisms underlying a possible decrease in LTL in PTSD are not fully known. LTL is approximately 70% genetically determined, 75 and telomeres are also subject to epigenetic modifications acquired over the lifespan. 76 Such processes could explain the possibility of LTL shortening preceding (and possibly being associated with risk of acquiring) PTSD. A major nongenetic or epigenetic determinant of LTL is repeated cell division, as might occur in leukocytes responding to chronic antigen exposure, in the absence of adequate telomerase activity. 77 The other major effectors of LTL shortening are oxidative stress, 78 which, as reviewed here, has equivocal evidence of increases in PTSD and chronic inflammation. A large number of studies have now reported increased inflammation in PTSD, 79 which offers one plausible explanation for LTL shortening.
Earlier Onset of Senescence-Associated Conditions
The reviewed evidence also suggests associations between PTSD and most of the age-associated medical illnesses targeted in this review, with the possible exception of HTN. The association of PTSD with such distinct medical conditions, which nevertheless share an association with aging, supports an accelerated aging model of PTSD.
The findings of senescence-related medical comorbidities are consistent with prior reviews focused on the elevated incidence and prevalence of cardiovascular disease in PTSD. 80, 81 The studies of dementia are consistent with many reports indicating worse cognitive performance in patients with PTSD.
A recent meta-analysis conducted by members of the current research team revealed that older adults with PTSD have greater than age-expected deficits in a range of cognitive domains, with particularly strong effects noted for processing speed, learning/memory, and executive functions. 82 Note that these are also among the domains most commonly affected by normal aging. 83 The increased cognitive impairment may also affect the risk of dementia because of lowered cognitive reserve. Although combat-related traumatic brain injury could conceivably explain some of the increased risk of dementia in PTSD, such an increase was also reported in one non-combat sample. 84 
Mortality
Seven of 10 studies reported increased mortality in PTSD, with the statistical analysis suggesting a mild to moderate association. This is consistent with an early onset or acceleration of senescence in PTSD.
Retrospective mortality analyses tend to be easier to conduct in military veteran settings (e.g., VA hospital systems) because of the availability of long-term retrospective administrative or clinical data sets. Nine of the 10 mortality studies included in the present review were conducted in military veteran sample; 85e93 the other study included veterans and other World War II survivors in a community sample in the Netherlands. 94 As mortality among military veterans may differ in form or overall rate from the general population, the observed overall mortality hazard ratio may not fully generalize to non-veteran PTSD populations. On the other hand, the non-PTSD comparison subjects in each of these studies were also war veterans, so general military/war experience was not a systematic bias or unilaterally confounded with PTSD status within these studies. In terms of mortality, it is difficult to say which causes of death should be included in any analysis. Suicides and accidents should perhaps be excluded, but if one is looking at mortality as an indicator of physiological aging, it is not clear that such exclusions are appropriate. For example, suicides of individuals who are suffering from severe impairments in functioning, or accidents due to age-related physical problems are relevant, but this information is usually not available in the published reports.
Additional Interpretive Limitations
Other potential interpretative limitations for this review reflect the fact that the present review required synthesis across a broad spectrum of studies that varied in outcomes using divergent methods. There was large variability among included studies in the subject selection criteria, the nature of the comparison samples, the nature of the index traumas, age at the index trauma, assessment methods, and the statistical analyses and reported results. Indeed, the variability in outcomes and available data for the medical comorbidity studies made calculation of meaningful pooled effect sizes questionable, so we focused that part of our review on whether the findings of each study supported an association of PTSD with the targeted medical condition rather than conducting meta-analytic estimates of pooled effect sizes. On the other hand, there was sufficient overlap to calculate pooled effect size estimates for several biomarkers (LTLs, CRP, IL-6, IL-1b, and TNFa) as well as in the mortality reports to calculate an average hazard ratio. Thus, the standard limitations of any meta-analyses are relevant, including publication bias toward studies with positive findings, and heterogeneity in the specific design and nature of component studies. 95, 96 In addition, many of these findings could reflect associations of PTSD with other risk factors such as smoking and alcohol consumption, lack of exercise, and poor nutrition. A number of the reviewed studies were limited in terms of their assessment of some potential risk factors such as the number and severity of traumas, duration of PTSD, concomitant injuries, and types of treatment received by the patients. Another limitation is that any individual increase in a senescence-associated biomarker does not necessarily prove an association with senescence per se, as the biomarker may be altered in other conditions as well.
This review intentionally focused on comorbidity of several specific conditions that are potentially fatal, known to increase in incidence with normal aging, and worsened by stress. It is possible, however, that PTSD is associated with increased general medical comorbidity and not just age-related morbidity. That is, PTSD may be bad for one's biological and neurocognitive health, irrespective of a specific age-related process. On the other hand, most medical health problems are adversely affected by normal aging, making it difficult to identify comparator conditions that are definitively not age-related.
Key Questions
Is There Evidence for Early or Accelerated Senescence In PTSD? Overall, the reviewed empirical literature suggested early senescence in PTSD. There is a question of whether the mortality rate curve, usually modeled with the exponential Gompertz mortality function, 97 is left-shifted toward a younger age (premature senescence), resulting in senescence occurring earlier due to a higher initial mortality rate, versus whether the exponential curve rises at a faster rate-a true acceleration of senescence. (The Gompertz function is an empirical population model for mortality rates which is usually expressed as an exponential function; the slope of the line represents the acceleration of mortality rate with age, which gives an estimate of the rate of senescence.) In both of these cases, which are not mutually exclusive, there would be a higher mortality rate at a given age. To our knowledge, no studies have been performed in PTSD or any other psychiatric disorders in which the Gompertz rate has been estimated. Thus, there is no direct evidence of "accelerated" senescence in any psychiatric condition at this time. But, if PTSD were associated with not just earlier but accelerated aging, comorbid medical conditions could continue to evolve at an accelerated pace. Furthermore, one would expect that any intervention affecting core aging processes might open the field to a new set of therapeutic approaches. For PTSD, this could mean using drugs that have been considered for their possible anti-aging potential, such as anti-inflammatory medications.
What are the Potential Protective or Risk Factors for Early Senescence In PTSD? Is any increase in senescence-related morbidity associated with PTSD itself; with other health-related behavioral changes associated with PTSD, such as increased smoking, drug use, or suicidal behavior; or with other factors such as gender or treatment? This question cannot be answered with certainty at this time. Few studies specifically focused on sex differences in PTSDrelated early senescence. 29 Treatment or improvement of PTSD may also influence senescence effects, which is supported by the study of Gill et al., 40 in which CRP and IL-6 were elevated in women who had current PTSD, but not in those who had recovered from PTSD, and the study of Zohar et al., 93 which did not report an association of PTSD with increased mortality, but in which all the participants had received aggressive monitoring and treatment for PTSD.
What are the Possible Mechanisms of Early Senescence In PTSD? Mechanisms of early senescence in PTSD may depend on the type of association between the two, and there are several possibilities-again, not mutually exclusive. First, individuals vulnerable to early senescence processes may also be more vulnerable to developing PTSD. 24 Second, traumatic events that precipitate PTSD may affect the initial mortality rate of individuals. For example, survivors of trauma may have earlier mortality because of complications from physical injuries rather than PTSD. Third, PTSD may be associated with ongoing physiological processes that increase the rate of senescence over time, for example, inflammation. The pathways by which inflammatory or other senescence-related processes could be maintained after the initial trauma are unknown, but could involve increased allostatic load, where neural mechanisms are utilized to maintain optimal functioning under changing stressors. Allostatic mechanisms are hypothesized to be utilized to anticipate the effects of stressors and address them to preserve optimal functioning with the least cost. 98 The sum of the changes in allostatic mechanisms (including blood concentrations of cortisol, norepinephrine, epinephrine, cholesterol, and glycosylated hemoglobin, as well as blood pressure and heart rate variability) in response to anticipated stressors is called allostatic load. An increase in allostatic load may be associated with obesity, HTN, hyperlipidemia, and atherosclerosis, and may be involved in mechanisms for the development of ulcer disease and cardiovascular disorders. 99, 100 Studies have reported abnormalities in allostatic load in PTSD, 101 and it may be important to determine how these relate to biological indicators of senescence and to medial morbidity and mortality.
Suggestions for Future Research
The present review does not speak to whether accelerated aging is specific to PTSD. As we noted earlier, there have been suggestions that medical comorbidity in some other psychiatric conditions, including schizophrenia, bipolar disorder, and major depression, reflect an acceleration of the aging process.
1e4 Among studies in the present review there were isolated reports that, in addition to normative comparison samples, included other psychiatric conditions as potential comparison groups, but we intentionally focused our literature search and review on comparisons of people with PTSD to psychiatrically healthy comparison subjects. But even if PTSD is only one of several psychiatric conditions associated with accelerated aging, the relative precision with which one can identify the time of the proximal causal traumatic event in PTSD affords a relatively unique research opportunity. That is, the relative precision with which onset can be estimated among people with PTSD relative to other psychiatric conditions may allow researchers and clinicians to better characterize the trajectory of such change, such as whether the added comorbidity occurs soon after illness onset or continues to accelerate in the course of years living with the disorder, as well as whether treatment of the psychiatric symptoms of PTSD alters that course. We recommend that future studies focus on issues of premature versus accelerated senescence, senescence-associated versus non-senescenceassociated medical comorbidities, and greater specifics about the nature of inflammatory, oxidative, cellular aging, and allostatic processes that may be involved in PTSD, as well as about the nature of the trauma-type, intensity, recurrence, and developmental timing. To address one of the potential mechanisms we noted previously-that earlier mortality may be due to physical injuries rather than PTSD-studies could compare individuals with PTSD who incurred injuries during the traumatic event to those with PTSD who did not. In addition, it would be important to learn exactly how biological indicators of senescence may be relevant to future therapeutic efforts, perhaps enabling more personalized treatment. As we noted, only a few isolated studies considered remitted versus non-remitted PTSD (see earlier discussion of Gill et al. 40 and
Zohar et al. 93 ), and/or directly compared those with full versus "partial" PTSD. Thus, another set of key questions for further research is the importance and timing of PTSD syndromal status-that is, does accelerated aging occur even after the psychiatric symptoms have remitted and/or among those who show most but not full PTSD symptoms? Finally, we urge scientists to investigate the public health consequences of early aging and PTSD.
Conclusions and Implications
We believe these findings suggest a need to reconceptualize PTSD as being more than a mental illness. Early senescence and increased medical morbidity and premature mortality in PTSD have implications for healthcare beyond simply the treatment of PTSD symptoms, and warrant a more integrated medicalepsychiatric approach. At a time when people are generally aging better (delaying social security, living longer, etc.), there may be a subgroup of people that is moving in the opposite direction. This has obvious humanitarian and healthcare cost implications. 
